Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

To make things a little less confusing, we’re here with all the info you need about popular weight loss med Mounjaro.

Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...

Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster ...

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...

Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Eli Lilly shares fell after the company’s oral drug showed less weight loss than hoped. It could still be huge.

FOR years, Emma Morris hid from cameras, avoided mirrors and felt like a prisoner in her own body because of her weight. But ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...